


PHARMACEUTICAL 2023



IMPEL PHARMACEUTICALS INC Rank 383 of 446





PHARMACEUTICAL 2023



IMPEL PHARMACEUTICALS INC Rank 383 of 446

The relative strengths and weaknesses of IMPEL PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IMPEL PHARMACEUTICALS INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 34% points. The greatest weakness of IMPEL PHARMACEUTICALS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 73% points.

The company's Economic Capital Ratio, given in the ranking table, is -165%, being 208% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	79,809
Cost of Goods Sold	6,495
Intangible Assets	0
Liabilities, Current	22,163
Liabilities, Non-Current	49,645
Other Assets	4,878
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	60,899
Other Net Income	-23,128
Other Revenues	12,652
Property and Equipment	3,863
Research and Development	11,456
Selling, General and Administrative Expense	77,885

Output Variable	Value in 1000 USD
Assets	88,550
Liabilities	132,707
Expenses	95,836
Revenues	12,652
Stockholders Equity	-44,157
Net Income	-106,312
Comprehensive Net Income	-106,312
Economic Capital Ratio	-165%